Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
2018
Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with high-risk cytogenetic abnormalities. Several cases of invasive aspergillosis have recently been reported in ibrutinib-treated patients. We report two cases of cerebral aspergillosis in CLL patients treated with ibrutinib.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
8
Citations
NaN
KQI